Drug Discovery, Drug Research Editorial
-
Targeting RNA With Small Molecules
7/25/2023
Beyond mRNA's dogmatic role as the intermediate in gene expression, non-coding RNA play essential roles in transcription regulation, maturation, and translation. This article explores the potential of RNA as a clinically validated avenue for drug development, methods for design and discovery, and implications for the future of medicine.
-
6 Emerging Trends In Using Stem Cell Assays
7/24/2023
Stem cell assays allow scientists to assess the self-renewal capacity, proliferation rate, differentiation potential, and other characteristics of stem cells. By understanding how stem cells respond to different conditions, scientists can optimize protocols for therapeutic use. Let's look at six emerging trends in using stem cell assays.
-
FDA Finalizes Guidance On Nonclinical Evaluation Of Pharmaceutical Immunotoxicity
7/18/2023
The FDA has now finalized a guidance document on the immunotoxic potential of pharmaceuticals. The FDA builds on current ICH guidance and proposes a two-stage approach. Central to the guidance is using a risk framework.
-
Using AI In Drug Discovery Isn’t The Golden Solution You Think It Is — Yet.
7/17/2023
Before we realize the true potential of advanced artificial intelligence (AI) and machine learning (ML) technologies to treat disease, we need to start by developing technologies that can generate the massive amounts of reliable, high-quality biological data that make up the fundamentals of any AI/ML approach.
-
Protein Degraders: Progress, Limitations, & Future Directions
7/12/2023
There is great excitement surrounding the development of small molecules that trigger the degradation of proteins. This article will highlight proteolysis targeting chimeras (PROTACs), their current limitations, and the emerging strategies to address those limitations, resulting in a bright future for targeted protein degradation.
-
Patenting Functionally Claimed Biological Compounds After Amgen V. Sanofi
7/10/2023
Snell & Wilmer attorneys discuss the recent SCOTUS decision to uphold the Federal Circuit's holding that Amgen’s patent claims for functionally claimed antibodies were invalid for failing to meet the enablement requirement. The attorneys share what this means for the industry going forward.
-
Targeting SORT1 To Drive Peptide–Drug Conjugates In Oncology
7/3/2023
Peptide-drug conjugates — therapies that generally employ a cleavable or non-cleavable linker to attach a receptor-targeting peptide to a drug payload — have emerged as a potentially viable modality for targeted cancer treatment. How do they work? And how is the glycoprotein SORT1 one of the most promising targets?
-
The FDA’s Sway On AI
6/29/2023
The FDA’s CDER published a paper titled “Artificial Intelligence in Drug Manufacturing" to facilitate input from outside the agency. Here's some of that input from Chief Editor Louis Garguilo.
-
3 Updated Fundamentals Of Outsourcing
6/26/2023
Here are three newly updated key factors for increasing your chances of personal, programmatic, and organizational success, as you pursue the activities known collectively as drug development and manufacturing outsourcing.
-
A Brief Overview Of Epigenetics
6/26/2023
Epigenetics is an emerging domain of scientific research that studies how the environment and behaviors can cause changes that affect the way genes work. This article shares a brief overview of the space.